This can only be good news for early stage life science companies.
RiverVest Venture Partners has announced the closing of its Fund V with $275 million of capital commitments in an oversubscribed fundraise. This brings the St. Louis-based firm’s total assets under management to more than $1.6 billion.
RiverVest invests in early stage biopharma and medical device companies addressing significant unmet medical needs and has delivered consistently strong results to investors. Fund V is the firm’s largest fund to date, reflecting commitments from a wide range of institutional investors, as well as family offices and individual investors.
To learn more, click here.